Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Beacon Topco, Inc. filings on SEC EDGAR ↗
For the nine months ended September 30, 2026, Beacon Topco reported a net loss of $22.2 million, a significant reduction from the $55.4 million loss in the prior year period. The company maintained a cash position of $49.2 million and plans to rename itself Clywedog Therapeutics Holdings, Inc. following a pending merger transaction.
Beacon Topco M&A Deal with Clywedog Therapeutics, Inc.
Beacon Topco, Inc. entered into a third amendment to its merger agreement with Clywedog Therapeutics, Inc. and Barinthus Biotherapeutics plc. The amendment updates the expected closing timeline and extends the 'End Date' for the merger to November 13, 2026.
Beacon Topco M&A Deal with Clywedog Therapeutics, Inc.
Beacon Topco, Inc. entered into a second amendment to its merger agreement with Clywedog Therapeutics, Inc., extending the expected closing date and the 'End Date' to October 31, 2026. The filing also disclosed positive Phase 1b clinical trial results for Clywedog's type 2 diabetes candidate, balomenib, which showed sustained glycemic improvement three months after treatment ended.